How does LYMFE's PB Ratio compare to its peers?

Insufficient data to calculate LYMFE's Price-To-Book Ratio vs. peers for valuation analysis.

How does LYMFE's PB Ratio compare vs other companies in the CH Capital Markets Industry?

Insufficient data to calculate LYMFE's Price-To-Book Ratio vs. industry for valuation analysis.

What is LYMFE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate LYMFE's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of LYMFE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate LYMFE's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Multi Units Luxembourg SICAV - Amundi MSCI EMU SWX:LYMFE Stock Report

Last Price

€61.26

Market Cap

€0

7D

-2.0%

1Y

6.0%

Updated

23 Dec, 2024

Data

Company Financials

Multi Units Luxembourg SICAV - Amundi MSCI EMU

SWX:LYMFE Stock Report

Market Cap: €0

LYMFE Stock Overview

No business description. More details

LYMFE fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	1/6

My Notes

Capture your thoughts, links and company narrative

Multi Units Luxembourg SICAV - Amundi MSCI EMU Competitors

Price History & Performance

Summary of share price highs, lows and changes for Multi Units Luxembourg SICAV - Amundi MSCI EMU
Historical stock prices
Current Share Price	€61.26
52 Week High	€65.22
52 Week Low	€57.23
Beta	0
1 Month Change	-1.78%
3 Month Change	-4.01%
1 Year Change	6.02%
3 Year Change	4.86%
5 Year Change	21.72%
Change since IPO	24.11%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	LYMFE	CH Capital Markets	CH Market
7D	-2.0%	-3.6%	-1.6%
1Y	6.0%	6.7%	1.5%

Return vs Industry: LYMFE matched the Swiss Capital Markets industry which returned 5.5% over the past year.

Return vs Market: LYMFE exceeded the Swiss Market which returned 0.7% over the past year.

Price Volatility

Is LYMFE's price volatile compared to industry and market?
LYMFE volatility
LYMFE Average Weekly Movement	1.7%
Capital Markets Industry Average Movement	3.1%
Market Average Movement	3.2%
10% most volatile stocks in CH Market	7.4%
10% least volatile stocks in CH Market	1.6%

Stable Share Price: LYMFE has not had significant price volatility in the past 3 months compared to the Swiss market.

Volatility Over Time: LYMFE's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	n/a

Multi Units Luxembourg SICAV - Amundi MSCI EMU Fundamentals Summary

How do Multi Units Luxembourg SICAV - Amundi MSCI EMU's earnings and revenue compare to its market cap?
LYMFE fundamental statistics
Market cap	n/a
Earnings (TTM)	€0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is LYMFE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LYMFE income statement (TTM)
Revenue	€0
Cost of Revenue	€0
Gross Profit	€0
Other Expenses	€0
Earnings	€0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did LYMFE perform over the long term?

See historical performance and comparison

Dividends

2.9%

Current Dividend Yield

n/a

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 18:09
End of Day Share Price	2024/12/23 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Multi Units Luxembourg SICAV - Amundi MSCI EMU is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution